Perforin: An intriguing protein in allograft rejection immunology (Review)
- Authors:
- Ana-Maria Pașatu-Cornea
- Elena Ciciu
- Liliana-Ana Tuță
-
Affiliations: Department of Nephrology, Constanta County Emergency Hospital, 900591 Constanta, Romania - Published online on: June 15, 2022 https://doi.org/10.3892/etm.2022.11446
- Article Number: 519
This article is mentioned in:
Abstract
 |
 |
|
Covic A, Mircescu G, Gluhovschi G and Schiller A: Ghiduri de practica medicala. Boala cronica de rinichi. 1-109. 2007. Bucuresti AG de practica medicala. SR de N: No Title. | |
|
Evans RW, Manninen DL, Garrison LP Jr, Hart LG, Blagg CR, Gutman RA, Hull AR and Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med. 312:553–559. 1985.PubMed/NCBI View Article : Google Scholar | |
|
Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C and Muirhead N: A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 50:235–242. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Simmons RG and Abress L: Quality-of-life issues for end-stage renal disease patients. Am J Kidney Dis. 15:201–208. 1990.PubMed/NCBI View Article : Google Scholar | |
|
Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY and Port FK: Long-term survival in renal transplant recipients with graft function. Kidney Int. 57:307–313. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Organ procurement and transplantation network and scientific registry of transplant recipients 2010 data report. Am J Transplant. 12 (Suppl 1):S1–S156. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Foroutan F, Friesen EL, Clark KE, Motaghi S, Zyla R, Lee Y, Kamran R, Ali E, De Snoo M, Orchanian-Cheff A, et al: Risk factors for 1-year graft loss after kidney transplantation systematic review and meta-analysis. Clin J Am Soc Nephrol. 14:1642–1650. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wyburn KR, Jose MD, Wu H, Atkins RC and Chadban SJ: The role of macrophages in allograft rejection. Transplantation. 80:1641–1647. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Williams TM: Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagnostics. 3:98–104. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC Jr, Wright MW, et al: Gene map of the extended human MHC. Nat Rev Genet. 5:889–899. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Sayegh MH and Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med. 338:1813–1821. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Osińska I, Popko K and Demkow U: Perforin: An important player in immune response. Cent Eur J Immunol. 39:109–115. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Mukherjee S and Mukherjee U: A comprehensive review of immunosuppression used for liver transplantation. J Transplant. 2009(701464)2009.PubMed/NCBI View Article : Google Scholar | |
|
Bull MR, Spicer JA, Huttunen KM, Denny WA, Ciccone A, Browne KA, Trapani JA and Helsby NA: The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agents. Eur J Drug Metab Pharmacokinet. 40:417–425. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lu P, Garcia-Sanz JA, Lichtenheld MG and Podack ER: Perforin expression in human peripheral blood mononuclear cells: Definition of an IL-2-independent pathway of perforin induction in CD8+ T cells. J Immunol. 148:3354–3360. 1992.PubMed/NCBI | |
|
Pipkin ME, Ljutic B, Cruz-Guilloty F, Nouzova M, Rao A, Zúñiga-Pflücker JC and Lichtenheld MG: Chromosome transfer activates and delineates a locus control region for perforin. Immunity. 26:29–41. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Keefe D, Shi L, Feske S, Massol R, Navarro F, Kirchhausen T and Lieberman J: Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity. 23:249–262. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Kägi D, Ledermann B, Bürki K, Zinkernagel RM and Hengartner H: Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol. 14:207–232. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Henkart PA: Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 3:31–58. 1985.PubMed/NCBI View Article : Google Scholar | |
|
Fujinaka H, Yamamoto T, Feng L, Nameta M, Garcia G, Chen S, El-shemi AA, Ohshiro K, Katsuyama K, Yoshida Y, et al: Anti-perforin antibody treatment ameliorates experimental crescentic glomerulonephritis in WKY rats. Kidney Int. 72:823–830. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Cecka JM, Cho YW and Terasaki PI: Analyses of the UNOS scientific renal transplant registry at three years-early events affecting transplant success. Transplantation. 53:59–63. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Mitchell RN and Libby P: Vascular remodeling in transplant vasculopathy. Circ Res. 100:967–978. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R and Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation. 55:752–756; discussion 756-7. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Miltenburg AM, Meijer-Paape ME, Daha MR, van Bockel JH, Weening JJ, van Es LA and van*der*Woude FJ: Donor-specific lysis of human kidney proximal tubular epithelial cells by renal allograft-infiltrating lymphocytes. Transplantation. 48:296–302. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Wever PC, Boonstra JG, Laterveer JC, Hack CE, van Der Woude FJ, Daha MR and ten*Berge IJ: Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft reaction. Transplantation. 66:259–264. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Cecka JM: The UNOS scientific renal transplant registry-2000. Clin Transpl. 1-18:2000.PubMed/NCBI | |
|
Owen WF and Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 54:627–636. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Guessous I, Ponte B, Marques-Vidal P, Paccaud F, Gaspoz JM, Burnier M, Waeber G, Vollenweider P and Bochud M: Clinical and biological determinants of kidney outcomes in a population-based cohort study. Kidney Blood Press Res. 39:74–85. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Csaba P, Kovesdy*Kopple JD and Kalantar-Zadeh K: Inflammation in renal insufficiency. UpToDate, 2011. | |
|
López-Gómez JM, Pérez-Flores I, Jofré R, Carretero D, Rodríguez-Benitez P, Villaverde M, Pérez-García R, Nassar GM, Niembro E and Ayus JC: Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol. 15:2494–2501. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Mas VR, Mas LA, Archer KJ, Yanek K, King AL, Gibney EM, Cotterell A, Fisher RA, Posner M and Maluf DG: Evaluation of gene panel mrnas in urine samples of kidney transplant recipients as a non-invasive tool of graft function. Mol Med. 13:315–324. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Choy JC: Granzymes and perforin in solid organ transplant rejection. Cell Death Differ. 17:567–576. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Hameed A, Truong LD, Price V, Kruhenbuhl O and Tschopp J: Immunohistochemical localization of granzyme B antigen in cytotoxic cells in human tissues. Am J Pathol. 138:1069–1075. 1991.PubMed/NCBI | |
|
Griffiths GM, Namikawa R, Mueller C, Liu CC, Young JD, Billingham M and Weissman I: Granzyme A and perforin as markers for rejection in cardiac transplantation. Eur J Immunol. 21:687–692. 1991.PubMed/NCBI View Article : Google Scholar | |
|
Ciément MV, Haddad P, Soulié A, Benvenuti C, Lichtenheld MG, Podack ER, Sigaux N and Sasportes M: Perform and granzyme B as markers for acute rejection in heart transplantation. Int Immunol. 3:1175–1181. 1991.PubMed/NCBI View Article : Google Scholar | |
|
Lipman ML, Stevens AC and Strom TB: Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol. 152:5120–5127. 1994.PubMed/NCBI | |
|
Kummer JA, Wever PC, Kamp AM, ten Berge IJ, Hack CE and Weening JJ: Expression of granzyme A and B proteins by cytotoxic lymphocytes involved in acute renal allograft rejection. Kidney Int. 47:70–77. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Krams SM, Villanueva JC, Quinn MB and Martinez OM: Expression of the cytotoxic T cell mediator granzyme B during liver allograft rejection. Transpl Immunol. 3:162–166. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Legros-Maïda S, Soulié A, Benvenuti C, Wargnier A, Vallée N, Berthou C, Guillet J, Sasportes M and Sigaux N: Granzyme B and perforin can be used as predictive markers of acute rejection in heart transplantation. Eur J Immunol. 24:229–233. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Yannaraki M, Rebibou JM, Ducloux D, Saas P, Duperrier A, Felix S, Rifle G, Chalopin JM, Hervé P, Tiberghien P and Ferrand C: Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection. Transpl Int. 19:759–768. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B, Serur D, Mouradian J, Schwartz JE and Suthanthiran M: Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med. 344:947–954. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Graziotto R, Del Prete D, Rigotti P, Anglani F, Baldan N, Furian L, Valente M, Antonello A, Marchini F, D'Angelo A and Gambaro G: Perforin, Granzyme B, and Fas ligand for molecular diagnosis of acute renal-allograft rejection: Analyses on serial biopsies suggest methodological issues. Transplantation. 81:1125–1132. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Strehlau J, Pavlakis M, Lipman M, Shapiro M, Vasconcellos L, Harmon W and Strom TB: Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA. 94:695–700. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Campistol JM, Iñigo P, Larios S, Bescos M and Oppenheimer F: Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant. 16 (Suppl 1):S114–S116. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Nocera A, Tagliamacco A, De Palma R, Del Galdo F, Ferrante A, Fontana I, Barocci S, Ginevri F, Rolla D, Ravetti JL and Valente U: Cytokine mRNA expression in chronically rejected human renal allografts. Clin Transplant. 18:564–570. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Pribylova-Hribova P, Kotsch K, Lodererova A, Viklicky O, Vitko S, Volk HD and Lacha J: TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction. Kidney Int. 69:1872–1879. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Shin GT, Kim SJ, Lee TS, Oh CK and Kim H: Gene expression of perforin by peripheral blood lymphocytes as a marker of acute rejection. Nephron Clin Pract. 100:c63–c70. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Trapani JA and Smyth MJ: Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2:735–747. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Pascoe MD, Marshall SE, Welsh KI, Fulton LM and Hughes DA: Increased accuracy of renal allograft rejection diagnosis using combined perforin, granzyme B, and Fas ligand fine-needle aspiration immunocytology. Transplantation. 69:2547–2553. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Ajith A, Portik-Dobos V, Nguyen-Lefebvre AT, Callaway C, Horuzsko DD, Kapoor R, Zayas C, Maenaka K, Mulloy LL and Horuzsko A: HLA-G dimer targets Granzyme B pathway to prolong human renal allograft survival. FASEB J. 33:5220–5236. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tampio J, Huttunen J, Montaser A and Huttunen KM: Targeting of perforin inhibitor into the brain parenchyma via a prodrug approach can decrease oxidative stress and neuroinflammation and improve cell survival. Mol Neurobiol. 57:4563–4577. 2020.PubMed/NCBI View Article : Google Scholar | |
|
D'Angelo ME, Dunstone MA, Whisstock JC, Trapani JA and Bird PI: Perforin evolved from a gene duplication of MPEG1, followed by a complex pattern of gene gain and loss within Euteleostomi. BMC Evol Biol. 12(59)2012.PubMed/NCBI View Article : Google Scholar | |
|
Araujo-Voces M and Quesada V: Frequent birth-and-death events throughout perforin-1 evolution. BMC Evol Biol. 20(135)2020.PubMed/NCBI View Article : Google Scholar | |
|
De Rosa SC, Andrus JP, Perfetto SP, Mantovani JJ, Herzenberg LA, Herzenberg LA and Roederer M: Ontogeny of gamma delta T cells in humans. J Immunol. 172:1637–1645. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP and Ley TJ: Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 21:589–601. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Gumperz JE, Miyake S, Yamamura T and Brenner MB: Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 195:625–636. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Nakata M, Kawasaki A, Azuma M, Tsuji K, Matsuda H, Shinkai Y, Yagita H and Okumura K: Expression of perforin and cytolytic potential of human peripheral blood lymphocyte subpopulations. Int Immunol. 4:1049–1054. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Brennan AJ, Chia J, Trapani JA and Voskoboinik I: Perforin deficiency and susceptibility to cancer. Cell Death Differ. 17:607–615. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Voskoboinik I, Smyth MJ and Trapani JA: Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol. 6:940–952. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Salcedo TW, Azzoni L, Wolf SF and Perussia B: Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol. 151:2511–2520. 1993.PubMed/NCBI | |
|
Zhang J, Scordi I, Smyth MJ and Lichtenheld MG: Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med. 190:1297–1308. 1999.PubMed/NCBI View Article : Google Scholar | |
|
García-Sanz JA and Podack ER: Regulation of perforin gene expression in a T cell hybrid with inducible cytolytic activity. Eur J Immunol. 23:1877–1883. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Uellner R, Zvelebil MJ, Hopkins J, Jones J, MacDougall LK, Morgan BP, Podack E, Waterfield MD and Griffiths GM: Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J. 16:7287–7296. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Pipkin ME and Lichtenheld MG: A reliable method to display authentic DNase I hypersensitive sites at long-ranges in single-copy genes from large genomes. Nucleic Acids Res. 34(e34)2006.PubMed/NCBI View Article : Google Scholar | |
|
Podack ER and Dennert G: Assembly of two types of tubules with putative cytolytic function by cloned natural killer cells. Nature. 302:442–445. 1983.PubMed/NCBI View Article : Google Scholar | |
|
Podack ER, Young JD and Cohn ZA: Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci USA. 82:8629–8633. 1985.PubMed/NCBI View Article : Google Scholar | |
|
Young JD, Cohn ZA and Podack ER: The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: Structural, immunological, and functional similarities. Science. 233:184–190. 1986.PubMed/NCBI View Article : Google Scholar | |
|
Young JD, Hengartner H, Podack ER and Cohn ZA: Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell. 44:849–859. 1986.PubMed/NCBI View Article : Google Scholar | |
|
Lowrey DM, Aebischer T, Olsen K, Lichtenheld M, Rupp F, Hengartner H and Podack ER: Cloning, analysis, and expression of murine perforin 1 cDNA, a component of cytolytic T-cell granules with homology to complement component C9. Proc Natl Acad Sci USA. 86:247–251. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Shinkai Y, Takio K and Okumura K: Homology of perforin to the ninth component of complement (C9). Nature. 334:525–527. 1988.PubMed/NCBI View Article : Google Scholar | |
|
Tschopp J, Masson D and Stanley KK: Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature. 322:831–834. 1986.PubMed/NCBI View Article : Google Scholar | |
|
Lichtenheld MG, Olsen KJ, Lu P, Lowrey DM, Hameed A, Hengartner H and Podack ER: Structure and function of human perforin. Nature. 335:448–451. 1988.PubMed/NCBI View Article : Google Scholar | |
|
Blumenthal R, Millard PJ, Henkart MP, Reynolds CW and Henkart PA: Liposomes as targets for granule cytolysin from cytotoxic large granular lymphocyte tumors. Proc Natl Acad Sci USA. 81:5551–5555. 1984.PubMed/NCBI View Article : Google Scholar | |
|
Henkart PA, Yue CC, Yang J and Rosenberg SA: Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells. J Immunol. 137:2611–2617. 1986.PubMed/NCBI | |
|
Müllbacher A, Waring P, Tha Hla R, Tran T, Chin S, Stehle T, Museteanu C and Simon MM: Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci USA. 96:13950–13955. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Nakajima H, Park HL and Henkart PA: Synergistic roles of granzymes A and B in mediating target cell death by rat basophilic leukemia mast cell tumors also expressing cytolysin/perforin. J Exp Med. 181:1037–1046. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Shi L, Mai S, Israels S, Browne K, Trapani JA and Greenberg AH: Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med. 185:855–866. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Spicer BA, Conroy PJ, Law RHP, Voskoboinik I and Whisstock JC: Perforin-A key (shaped) weapon in the immunological arsenal. Semin Cell Dev Biol. 72:117–123. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Voskoboinik I, Whisstock JC and Trapani JA: Perforin and granzymes: Function, dysfunction and human pathology. Nat Rev Immunol. 15:388–400. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, Voskoboinik I and Trapani JA: Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 212:307–317. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Voskoboinik I, Thia MC, Fletcher J, Ciccone A, Browne K, Smyth MJ and Trapani JA: Calcium-dependent plasma membrane binding and cell lygis by perforin are mediated through its C2 domain: A critical role for aspartate residues 429, 435, 483, and 485 but not 491. J Biol Chem. 280:8426–8434. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Taylor MA, Ward B, Schatzle JD and Bennett M: Perforin- and Fas-dependent mechanisms of natural killer cell-mediated rejection of incompatible bone marrow cell grafts. Eur J Immunol. 32:793–799. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Voskoboinik I and Trapani JA: Perforinopathy: A spectrum of human immune disease caused by defective perforin delivery or function. Front Immunol. 4(441)2013.PubMed/NCBI View Article : Google Scholar | |
|
Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J and Filipovich AH: Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet. 41:137–144. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Rubin TS, Zhang K, Gifford C, Lane A, Choo S, Bleesing JJ and Marsh RA: Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH. Blood. 129:2993–2999. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hernandez-Pigeon H, Jean C, Charruyer A, Haure MJ, Titeux M, Tonasso L, Quillet-Mary A, Baudouin C, Charveron M and Laurent G: Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation. Implication of granzyme B and perforin. J Biol Chem. 281:13525–13532. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Hernandez-Pigeon H, Jean C, Charruyer A, Haure MJ, Baudouin C, Charveron M, Quillet-Mary A and Laurent G: UVA Induces Granzyme B in Human Keratinocytes through MIF implication in extracellular matrix remodeling. J Biol Chem. 282:8157–8164. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Shrestha AC, Wijesundara DK, Masavuli MG, Mekonnen ZA, Gowans EJ and Grubor-Bauk B: Cytolytic perforin as an adjuvant to enhance the immunogenicity of DNA vaccines. Vaccines (Basel). 7(38)2019.PubMed/NCBI View Article : Google Scholar | |
|
Gargett T, Grubor-Bauk B, Garrod TJ, Yu W, Miller D, Major L, Wesselingh S, Suhrbier A and Gowans EJ: Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. Immunol Cell Biol. 92:359–367. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Gummow J, Li Y, Yu W, Garrod T, Wijesundara D, Brennan AJ, Mullick R, Voskoboinik I, Grubor-Bauk B and Gowans EJ: A Multiantigenic DNA vaccine that induces broad hepatitis C Virus-specific T-cell responses in mice. J Virol. 89:7991–8002. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Wijesundara DK, Yu W, Quah BJC, Eldi P, Hayball JD, Diener KR, Voskoboinik I, Gowans EJ and Grubor-Bauk B: Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by-dendritic cells in a time-dependent manner. Sci Rep. 7(8530)2017.PubMed/NCBI View Article : Google Scholar | |
|
Escher F, Kühl U, Lassner D, Stroux A, Gross U, Westermann D, Pieske B, Poller W and Schultheiss HP: High perforin-positive cardiac cell infiltration and male sex predict adverse long-term mortality in patients with inflammatory cardiomyopathy. J Am Heart Assoc. 6(e005352)2017.PubMed/NCBI View Article : Google Scholar |
